

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/223714 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 33/00 (2006.01)
A61K 31/00 (2006.01) C07K 16/28 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/060592

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:

21 April 2022 (21.04.2022)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/178,739 23 April 2021 (23.04.2021) US
63/245,285 17 September 2021 (17.09.2021) US
63/272,851 28 October 2021 (28.10.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **LINDHOLM, Catharina**; AstraZeneca AB,
SE-151 85 Södertälje (SE). **CHIA, Yen Lin**; AstraZeneca
Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437,
Wilmington, Delaware 19850-5437 (US). **TUMMALA,
Rajendra**; AstraZeneca Pharmaceuticals LP, 1800 Con-
cord Pike, P.O. Box 15437, Wilmington, Delaware
19850-5437 (US). **ROSKOS, Lorin**; MedImmune, LLC,
One MedImmune Way, Gaithersburg, Maryland 20878
(US). **ALMQUIST, Joachim**; AstraZeneca AB, SE-151
85 Södertälje (SE). **ROUSE, Tomas**; AstraZeneca AB,
SE-151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Milstein Building, Granta Park, Cambridge, Cam-
bridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION

(57) Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.



WO 2022/223714 A1